News | Radiation Therapy | May 30, 2017

Research Shows Breast Cancer Surgery Marker Associated With Smaller Radiation Volume

Presentation at American Society of Breast Surgeons annual meeting reports BioZorb 3-D implant helps more accurately target treatment

Research Shows Breast Cancer Surgery Marker Associated With Smaller Radiation Volume

Image courtesy of Kara Lynn Leonard, M.D.

May 30, 2017 — Patients who were implanted with the BioZorb 3-D bioabsorbable marker during their lumpectomy could be treated with smaller radiation volumes than patients who did not receive the marker, according to new research. The findings were presented at the recent American Society of Breast Surgeons (ASBrS) annual meeting, April 26-30 in Las Vegas. The difference in volumes was statistically significant.

A scientific poster by Kara Lynn Leonard, M.D. reported that patients who received the marker were treated with substantially less radiation than patients whose tumors were defined during the treatment planning stage with free clips or no clips.

Leonard concluded that "the BioZorb system may offer an advantage in more precisely defining the lumpectomy site and in sparing larger volumes of healthy breast tissue from radiation." The poster also said the implant is particularly helpful for boost planning.

The study was a retrospective analysis of women who had received radiation treatment for breast cancer in the radiation oncology department at Rhode Island Hospital, in Providence, R.I. The study covered all women treated at the department during the year-long span from May 2015 through April 2016. The data encompassed 117 patients — 42 of whom received a BioZorb implant and 75 who did not.

The researchers compared records of women who received the marker to the records of patients who were not implanted with the device. Most of the women who did not have the marker implanted were treated before the device was adopted for use by the department.

Among measurements recorded for each patient were the amount of tissue removed during each patient's lumpectomy, and the amount of radiation each patient was targeted to receive — that is, the tumor bed volume. The tumor bed volume was substantially smaller for the patients who received the BioZorb device, a difference that was statistically significant.

More accurate radiation has several potential benefits for breast cancer patients. It can help improve cosmetic outcomes as well as help to protect healthy body structures such as the heart and lungs from radiation exposure.
Leonard is a radiation oncologist at Rhode Island Hospital (Providence, R.I.) and an assistant professor of radiation oncology at The Warren Alpert Medical School of Brown University.

BioZorb is the first and only device, according to manufacturer Focal Therapeutics, that identifies in a reliable way the three-dimensional region where the tumor was removed. By suturing the implant to the tumor bed, the surgeon can more precisely indicate to the radiation oncologist where the cancer was located. Because of the marker's unique configuration, it allows oncoplastic surgery to be used for reconstructing the breast with the patient's own tissues, while at the same time delineating the tumor's previous location.

The marker consists of a framework made of a bioabsorbable material that holds six titanium clips. The implant serves as a guide for the radiation oncologist during planning of radiation treatments that are delivered after surgery. The device's framework slowly dissolves in the body over the course of a year or more. The marker clips remain at the surgical site and can be viewed for long-term monitoring. Studies have reported the complication rate such as infection (2-3 percent) is virtually the same as for lumpectomy surgery and follow-up radiation without the implant.

For more information: www.focalrx.com

Related Content

Volpara Solutions to Showcase VolparaEnterprise Live! at RSNA
News | Mammography | October 16, 2017
Volpara Solutions will introduce VolparaEnterprise Live!, a mammography quality control tool, at the 2016 Radiological...
TMIST Mammography Study Opens Enrollment
News | Mammography | October 16, 2017
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of...
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Stanford Trial Demonstrates Accuracy of Accuro Image-Guided Epidural System
News | Ultrasound Imaging | October 09, 2017
October 9, 2017 — A clinical trial conducted at Stanford University Medical Center...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
Overlay Init